Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype

Nature Neuroscience

Volumn 9, Issue 9, 2006, Pages 1134-1141

  Heurteaux, Catherine ^a   Lucas, Guillaume ^b   Guy, Nicolas ^a   El Yacoubi, Malika ^a   Thümmler, Susanne ^a   Peng, Xiao Dong ^b,d   Noble, Florence ^c   Blondeau, Nicolas ^a   Widmann, Catherine ^a   Borsotto, Marc ^a   Gobbi, Gabriella ^b   Vaugeois, Jean Marie ^a   Debonnel, Guy ^b   Lazdunski, Michel ^a  

^a CNRS   (France)

^b MCGILL UNIVERSITY   (Canada)

^c INSERM   (France)

^d NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CORTICOSTERONE; FLUOXETINE; PAROXETINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL TREK 1; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; GENE DELETION; KNOCKOUT MOUSE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STRESS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSIVE DISORDER; DRUG RESISTANCE; FLUOXETINE; GENE DELETION; GENOTYPE; MICE; MICE, KNOCKOUT; PHENOTYPE; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PYRAMIDAL CELLS; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 33748111816     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn1749     Document Type: Article

References (50)

1. Lapin, I. & Oxenkrug, G. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1, 132-136 (1969).
2. Coppen, A. The biochemistry of affective disorders. Br. J. Psychiatry 113, 1237-1264 (1967).
3. Delgado, P. et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol. Psychiatry 46, 212-220 (1999).
4. Nestler, E.J. et al. Neurobiology of depression. Neuron 34, 13-25 (2002).
5. Maes, M. & Meltzer, H. The serotonin hypothesis of major depression. in Psychopharmacology The Fourth Generation of Progress (eds. Bloom, F.E. & Kupfer, D.J.) 933-944 (Raven, New York, 1995).
6. Owens, M. Molecular and cellular mechanisms of antidepressant drugs. Depress. Anxiety 4, 153-159 (1996).
7. Haddjeri, N., Blier, P. & de Montigny, C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci. 18, 10150-10156 (1998).
8. Mayorga, A. et al. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. J. Pharmacol. Exp. Ther. 298, 1101-1107 (2001).
9. Fink, M. et al. Cloning, functional expression and brain localization of a novel unconventional outward rectifier K+ channel. EMBO J. 15, 6854-6862 (1996).
10. Lesage, F. & Lazdunski, M. Molecular and functional properties of two-pore-domain potassium channels. Am. J. Physiol. Renal Physiol. 279, F793-F801 (2000).
11. Patel, A.J. & Honore, E. Properties and modulation of mammalian 2P domain K+ channels. Trends Neurosci. 24, 339-346 (2001).
12. Patel, A.J. et al. A mammalian two pore domain mechano-gated S-like K+ channel. EMBO J. 17, 4283-4290 (1998).
13. Chemin, J. et al. Mechanisms underlying excitatory effects of group I metabotropic glutamate receptors via inhibition of 2P domain K+ channels. EMBO J. 22, 5403-5411 (2003).
14. Siegelbaum, S.A., Camardo, J.S. & Kandel, E.R. Serotonin and cyclic AMP close single K+ channels in Aplysia sensory neurones. Nature 299, 413-417 (1982).
15. Kandel, E.R. & Schwartz, J.H. Molecular biology of learning: modulation of transmitter release. Science 218, 433-443 (1982).
16. Talley, E.M., Solorzano, G., Lei, Q., Kim, D. & Bayliss, D.A. CNS distribution of members of the two-pore-domain (KCNK) potassium channel family. J. Neurosci. 21, 7491-7505 (2001).
17. Maingret, F. et al. TREK-1 is a heat-activated background K(+) channel. EMBO J. 19, 2483-2491 (2000).
18. Heurteaux, C. et al. TREK-1, a K(+) channel involved in neuroprotection and general anesthesia. EMBO J. 23, 2684-2695 (2004).
19. Porsolt, R.D., Le Pichon, M. & Jalfre, M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266, 730-732 (1977).
20. Nestler, E.J. et al. Preclinical models: status of basic research in depression. Biol. Psychiatry 52, 503-528 (2002).
21. Cryan, J.F., Page, M.E. & Lucki, I. Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur. J. Pharmacol. 436, 197-205 (2002).
22. Steru, L., Chermat, R., Thierry, B. & Simon, P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl.) 85, 367-370 (1985).
23. Ripoll, N., David, D., Dailly, E., Hascoet, M. & Bourin, M. Antidepressant-like effects in various mice strains in the tail suspension. Behav. Brain Res. 143, 193-200 (2003).
24. Cryan, J. & Holmes, A. The ascent of mouse: advances in modelling human depression and anxiety. Nat. Rev. Drug Discov. 4, 775-790 (2005).
25. Kameyama, T., Nagasaka, M. & Yamada, K. Effects of antidepressant drugs on a quickly-learned conditioned-suppression response in mice. Neuropharmacology 24, 285-290 (1985).
26. Maier, S. Learned helplessness and animal models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 8, 435-446 (1984).
27. Caldarone, B., George, T., Zachariou, V. & Picciotto, M. Gender differences in learned helplessness behavior are influenced by genetic background. Pharmacol. Biochem. Behav. 66, 811-817 (2000).
28. Caldarone, B. et al. Sex differences in response to oral amitriptyline in three animal models. Psychopharmacology (Berl.) 170, 94-101 (2003).
29. Fink, M. et al. A neuronal two P domain K+ channel stimulated by arachidonic acid and polyunsaturated fatty acids. EMBO J. 17, 3297-3308 (1998).
30. Reyes, R. et al. Immunolocalization of the arachidonic acid and mechanosensitive baseline TRAAK potassium channel in the nervous system. Neuroscience 95, 893-901 (2000).
31. Maingret, F., Fosset, M., Lesage, F., Lazdunski, M. & Honore, E. TRAAK is a mammalian neuronal mechano-gated K+ channel. J. Biol. Chem. 274, 1381-1387 (1999).
32. Sheline, Y.I., Wang, P.W., Gado, M.H., Csernansky, J.G. & Vannier, M.W. Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. USA 93, 3908-3913 (1996).
33. Heuser, I.J. et al. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am. J. Psychiatry 153, 93-99 (1996).
34. Hermann, G. et al. Stress-induced changes attributable to the sympathetic nervous system. J. Neuroimmunol. 53, 173-180 (1994).
35. Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809 (2003).
36. Malberg, J. Implications of adult hippocampal neurogenesis in antidepressant action. J. Psychiatry Neurosci. 29, 196-205 (2004).
37. Couillard-Despres, S. et al. Doublecortin expression levels in adult brain reflect neurogenesis. Eur. J. Neurosci. 21, 1-14 (2005).
38. Kennard, L.E. et al. Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br. J. Pharmacol. 144, 821-829 (2005).
39. Karson, C.N. et al. Human brain fluoxetine concentrations. J. Neuropsychiatry Clin. Neurosci. 5, 322-329 (1993).
40. Komoroski, R.A. et al. In vivo 19F spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn. Reson. Med. 31, 204-211 (1994).
41. Bolo, N.R. et al. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23, 428-438 (2000).
42. Redrobe, J., Dumont, Y., Fournier, A., Baker, G. & Quirion, R. Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides 26, 1394-1400 (2005).
43. Blier, P. & de Montigny, C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21, 91S-98S (1999).
44. Descarries, L., Watkins, K., Garcia, S. & Beaudet, A. The serotonin neurons in nucleus raphe dorsalis of adult rat: a light and electron microscope radioautographic study. J. Comp. Neurol. 207, 239-254 (1982).
45. Gross, C. et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416, 396-400 (2002).
46. Xu, X., Pan, Y. & Wang, X. mRNA expression of the lipid and mechano-gated 2P domain K+ channels. J. Neurogenet. 16, 263-269 (2002).
47. Caccia, S., Cappi, M., Fracasso, C. & Garattini, S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl.) 100, 509-514 (1990).
48. Gingrich, J.A. & Hen, R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology (Berl.) 155, 1-10 (2001).
49. Gobbi, G., Murphy, D.L., Lesch, K. & Blier, P. Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J. Pharmacol. Exp. Ther. 296, 987-995 (2001).
50. Kandel, E.R. & Spencer, W.A. Electrophysiology of hippocampal neurons. II. After-potentials and repetitive firing. J. Neurophysiol. 24, 243-259 (1961).